Table 2.
Virulence characteristics of reported confirmed VTEC cases in 2007–2010 including all cases, hospitalized cases only and haemolytic uraemic syndrome (HUS) cases only (based on The European Surveillance System data as provided by the European Centre for Disease Prevention and Control)
| Cases | Total† | Subtotal‡ | Virulence* gene detection | |||||
|---|---|---|---|---|---|---|---|---|
| eae, vtx1 | eae, vtx2 | eae, vtx1, vtx2 | vtx1 | vtx2 | vtx1, vtx2 | |||
| Hospitalized§¶ | 522 | 313 | 22 (7·0%) | 185 (59·1%) | 85 (27·2%) | 4 (1·3%) | 10 (3·2%) | 7 (2·2%) |
| HUS§ | 777 | 371 | 10 (2·7%) | 294 (79·2%) | 37 (10·0%) | 2 (0·5%) | 24 (6·5%) | 4 (1·1%) |
| All§ | 13 545 | 7278 | 612 (8·4%) | 4254 (58·5%) | 1642 (22·6%) | 295 (4·1%) | 287 (3·9%) | 188 (2·6%) |
eae, Intimin-coding gene; vtx1, verocytotoxin 1 gene; vtx2, verocytotoxin 2 gene.
Includes all reported confirmed VTEC cases in humans.
Includes the reported confirmed VTEC cases in humans for which the vtx-eae gene characteristics are reported.
The percentage (within parentheses) is calculated using the corresponding total number of cases (either 7218; 313 or 371) as denominator.
Data on hospitalizations have only been collected for the last two years (2009 and 2010).